OpenLB
Open Library of Bioscience
Advanced Search
Pediatric nephrology (Berlin, Germany)
Jul, 2010;25 (7): 1207-17.

The evolving place of incretin-based therapies in type 2 diabetes.

Baptist Gallwitz
Author Information
  1. Baptist Gallwitz: Medizinische Klinik IV, Otfried-Müller-Strasse 10, 72076, Tübingen, Germany. baptist.gallwitz@med.uni-tuebingen.de
PMID: 20130920 DOI: 10.1007/s00467-009-1435-z

Abstract

Treatment options for type 2 diabetes based on the action of the incretin hormone glucagon-like peptide-1 (GLP-1) were first introduced in 2005. These comprise the injectable GLP-1 receptor agonists solely acting on the GLP-1 receptor on the one hand and orally active dipeptidyl-peptidase inhibitors (DPP-4 inhibitors) raising endogenous GLP-1 and other hormone levels by inhibiting the degrading enzyme DPP-4. In adult medicine, both treatment options are attractive and more commonly used because of their action and safety profile. The incretin-based therapies stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner and carry no intrinsic risk of hypoglycaemia. GLP-1 receptor agonists allow weight loss, whereas DPP-4 inhibitors are weight neutral. This review gives an overview of the mechanism of action and the substances and clinical data available.

References

  1. Regul Pept. 2007 Jun 7;141(1-3):120-8 [PMID: 17276524]
  2. Ann Intern Med. 2007 Apr 3;146(7):477-85 [PMID: 17404349]
  3. N Engl J Med. 2008 May 1;358(18):1969-70; discussion 1971-2 [PMID: 18450614]
  4. Diabetes Care. 2007 Jun;30(6):1487-93 [PMID: 17353504]
  5. Diabetes. 2004 Mar;53(3):654-62 [PMID: 14988249]
  6. Life Sci. 2007 Jul 4;81(4):272-9 [PMID: 17583752]
  7. Diabetes Obes Metab. 2008 Jul;10(7):545-55 [PMID: 18518892]
  8. Am J Physiol Renal Physiol. 2009 Dec;297(6):F1647-55 [PMID: 19776173]
  9. Diabetes Obes Metab. 2008 May;10(5):376-86 [PMID: 18355324]
  10. Diabet Med. 2008 Feb;25(2):152-6 [PMID: 18201212]
  11. Diabetes Care. 2005 May;28(5):1083-91 [PMID: 15855571]
  12. IDrugs. 2008 Dec;11(12):906-17 [PMID: 19051153]
  13. Curr Med Res Opin. 2008 Feb;24(2):489-96 [PMID: 18182122]
  14. J Card Fail. 2006 Dec;12(9):694-9 [PMID: 17174230]
  15. Lancet. 2009 Feb 7;373(9662):473-81 [PMID: 18819705]
  16. Endocrinology. 1992 Jan;130(1):159-66 [PMID: 1309325]
  17. Diabetes Care. 2004 Nov;27(11):2628-35 [PMID: 15504997]
  18. Drugs Today (Barc). 2009 Feb;45(2):101-13 [PMID: 19343230]
  19. Br J Pharmacol. 2003 Sep;140(1):123-32 [PMID: 12967942]
  20. Drugs Today (Barc). 2005 Sep;41(9):563-78 [PMID: 16341288]
  21. Diabetologia. 2007 Feb;50(2):259-67 [PMID: 17160407]
  22. Diabetes Care. 2009 Jan;32(1):193-203 [PMID: 18945920]
  23. J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9 [PMID: 16912128]
  24. Diabetes Care. 2007 Dec;30(12):3017-22 [PMID: 17878242]
  25. Curr Opin Investig Drugs. 2006 Apr;7(4):338-43 [PMID: 16625820]
  26. Ann Endocrinol (Paris). 2008 Apr;69(2):164-5 [PMID: 18417092]
  27. Int J Clin Pract. 2007 Jan;61(1):171-80 [PMID: 17156104]
  28. J Clin Invest. 1993 Jan;91(1):301-7 [PMID: 8423228]
  29. Diabetes Obes Metab. 2007 Mar;9(2):194-205 [PMID: 17300595]
  30. J Gene Med. 2008 Mar;10(3):260-8 [PMID: 18085721]
  31. Diabetologia. 1993 Aug;36(8):741-4 [PMID: 8405741]
  32. Endocrinology. 2004 Jun;145(6):2653-9 [PMID: 15044356]
  33. Postgrad Med. 2009 May;121(3):5-15 [PMID: 19491535]
  34. N Engl J Med. 2008 May 1;358(18):1970-1; discussion 1971-2 [PMID: 18456920]
  35. Diabetes Care. 2009 Oct;32(10):1880-6 [PMID: 19592625]
  36. Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2401-8 [PMID: 16024574]
  37. Diabet Med. 2009 Mar;26(3):268-78 [PMID: 19317822]
  38. N Engl J Med. 2003 Jan 30;348(5):383-93 [PMID: 12556541]
  39. J Pharmacol Exp Ther. 2005 Jan;312(1):303-8 [PMID: 15356213]
  40. Diabetologia. 1979 Feb;16(2):75-85 [PMID: 32119]
  41. Curr Med Res Opin. 2008 Jan;24(1):275-86 [PMID: 18053320]
  42. N Engl J Med. 2008 Jun 12;358(24):2545-59 [PMID: 18539917]
  43. Diabetologia. 2005 Jul;48(7):1380-5 [PMID: 15915337]
  44. Curr Med Res Opin. 2009 Oct;25(10):2401-11 [PMID: 19650754]
  45. Diabetes Care. 2009 May;32(5):762-8 [PMID: 19196887]
  46. Pediatr Res. 2009 Apr;65(4):370-4 [PMID: 19092720]
  47. Expert Opin Emerg Drugs. 2008 Dec;13(4):593-607 [PMID: 19046129]
  48. Diabetes Care. 2009 Jan;32(1):84-90 [PMID: 18931095]
  49. Vasc Health Risk Manag. 2009;5(1):199-211 [PMID: 19436648]
  50. Diabet Med. 2008 Sep;25(9):1129-31 [PMID: 19183322]
  51. Clin Ther. 2009 Apr;31(4):806-15 [PMID: 19446153]
  52. Medscape J Med. 2008 Jul 28;10(7):171 [PMID: 18769687]
  53. Lancet. 2006 Nov 11;368(9548):1696-705 [PMID: 17098089]
  54. Clin Ther. 2007 Nov;29(11):2333-48 [PMID: 18158075]
  55. Diabetes Care. 2009 Sep;32(9):1649-55 [PMID: 19478198]
  56. Expert Opin Pharmacother. 2007 Oct;8(15):2593-608 [PMID: 17931093]
  57. Curr Med Res Opin. 2009 Apr;25(4):1019-27 [PMID: 19278373]
  58. Circulation. 2004 Aug 24;110(8):955-61 [PMID: 15313949]
  59. BMC Endocr Disord. 2008 Oct 27;8:14 [PMID: 18954434]
  60. Diabetes Obes Metab. 2009 Aug;11(8):786-94 [PMID: 19476474]
  61. Horm Metab Res. 2008 Jun;40(6):427-30 [PMID: 18401832]
  62. Diabetes Care. 2005 May;28(5):1092-100 [PMID: 15855572]
  63. Vasc Health Risk Manag. 2008;4(4):743-51 [PMID: 19065992]
  64. J Clin Endocrinol Metab. 2009 Apr;94(4):1379-85 [PMID: 19174495]
  65. Diabetologia. 1986 Jan;29(1):46-52 [PMID: 3514343]
  66. Lancet. 2008 Oct 4;372(9645):1240-50 [PMID: 18782641]
  67. Postgrad Med. 2009 May;121(3):16-25 [PMID: 19491536]
  68. Exp Neurol. 2007 Feb;203(2):293-301 [PMID: 17125767]
  69. Vasc Health Risk Manag. 2008;4(2):383-94 [PMID: 18561513]
  70. Diabetologia. 2002 Feb;45(2):195-202 [PMID: 11935150]
  71. Curr Med Res Opin. 2009 Oct;25(10):2361-71 [PMID: 19650752]
  72. Lancet. 2009 Jul 4;374(9683):39-47 [PMID: 19515413]
  73. Diabetes Care. 1996 Jun;19(6):580-6 [PMID: 8725855]
  74. J Fam Pract. 2008 Sep;57(9 Suppl):S10-8 [PMID: 18786339]
  75. J Clin Endocrinol Metab. 2009 Jul;94(7):2215-20 [PMID: 19584196]
  76. Diabetologia. 2006 Aug;49(8):1711-21 [PMID: 16802130]
  77. JAMA. 2009 Apr 15;301(15):1565-72 [PMID: 19366776]
  78. Endocrinology. 2003 Dec;144(12):5149-58 [PMID: 12960095]
  79. Gastroenterology. 2007 May;132(6):2131-57 [PMID: 17498508]
  80. Ann Intern Med. 2005 Oct 18;143(8):559-69 [PMID: 16230722]
  81. Ann Pharmacother. 2006 Oct;40(10):1777-84 [PMID: 16985091]
  82. Adv Ther. 2009 Mar;26(3):249-62 [PMID: 19330494]
  83. Int J Clin Pract. 2009 Sep;63(9):1395-406 [PMID: 19614786]
  84. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):522-57 [PMID: 19876795]
  85. J Clin Pharmacol. 2006 Aug;46(8):876-86 [PMID: 16855072]
  86. Adv Ther. 2009 May;26(5):488-99 [PMID: 19444391]
  87. Diabetes Care. 2009 Jul;32(7):1237-43 [PMID: 19366970]
  88. Am J Cardiol. 2008 Sep 1;102(5):646-7 [PMID: 18721530]
  89. Diabetes Care. 2009 Jul;32(7):1224-30 [PMID: 19289857]
  90. Diabetes Obes Metab. 2006 Mar;8(2):156-63 [PMID: 16448519]
  91. Am J Health Syst Pharm. 2005 Jan 15;62(2):173-81 [PMID: 15700891]
  92. Int J Clin Pract. 2006 Dec;60(12):1654-61 [PMID: 17109672]
  93. N Engl J Med. 2008 Oct 9;359(15):1577-89 [PMID: 18784090]
  94. Curr Med Res Opin. 2006 Oct;22(10):1939-47 [PMID: 17022853]
  95. Clin Endocrinol (Oxf). 2009 Mar;70(3):343-53 [PMID: 18771570]
  96. J Biol Chem. 1992 Apr 15;267(11):7402-5 [PMID: 1313797]
  97. Expert Opin Investig Drugs. 2009 Sep;18(9):1405-11 [PMID: 19678802]
  98. Mol Pharmacol. 2009 Sep;76(3):453-65 [PMID: 19487246]
  99. Novartis Found Symp. 2008;292:146-55; discussion 155-8, 202-3 [PMID: 19203097]
  100. Int J Clin Pract Suppl. 2008 Mar;(159):8-14 [PMID: 18269436]
  101. Diabetes. 2003 Jul;52(7):1786-91 [PMID: 12829647]
  102. Biochem Biophys Res Commun. 2009 Feb 27;380(1):44-9 [PMID: 19150338]

MeSH Term

Adolescent
Adult
Animals
Child
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase 4
Dipeptidyl-Peptidase IV Inhibitors
Disease Models, Animal
Glucagon
Glucagon-Like Peptide 1
Humans
Hypoglycemic Agents
Insulin
Insulin Secretion

Chemicals

Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
Insulin
Glucagon-Like Peptide 1
Glucagon
DPP4 protein, human
Dipeptidyl Peptidase 4
Comparative Study Journal Article Review

Word Cloud

Created with Highcharts 10.0.0GLP-1actionreceptorinhibitorsDPP-4optionstype2diabeteshormoneagonistsincretin-basedtherapiessecretionweightTreatmentbasedincretinglucagon-likepeptide-1firstintroduced2005compriseinjectablesolelyactingonehandorallyactivedipeptidyl-peptidaseraisingendogenouslevelsinhibitingdegradingenzymeadultmedicinetreatmentattractivecommonlyusedsafetyprofilestimulateinsulininhibitglucagonglucose-dependentmannercarryintrinsicriskhypoglycaemiaallowlosswhereasneutralreviewgivesoverviewmechanismsubstancesclinicaldataavailableevolvingplace

Similar Articles

Cited By